Liquidia's Yutrepia Found To Infringe Lung Treatment Patent

By Elliot Weld · October 1, 2026, 7:55 PM EDT

A Delaware federal judge has ruled that Liquidia was infringing two claims of a patent covering methods of treating pulmonary hypertension associated with interstitial lung disease by seeking approval to market...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

United Therapeutics Corporation v. Liquidia Technologies, Inc.

Case Number

1:23-cv-00975

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

September 05, 2023